Cellectis SA (NAS:CLLS)
$ 1.56 0 (0%) Market Cap: 154.13 Mil Enterprise Value: -15.24 Mil PE Ratio: 0 PB Ratio: 1.27 GF Score: 70/100

Cellectis SA at Citi Biotech Conference Transcript

Sep 04, 2019 / 05:30PM GMT
Release Date Price: $12.09 (+3.16%)
Yigal Dov Nochomovitz
Citigroup Inc, Research Division - Director

The next panel is cell therapy, up-and-comers in the cell therapy space. So it's my pleasure to introduce our 3 distinguished guests, from Atara the CEO, Pascal Touchon; and from Cellectis, André Choulika; and, of course, from Fate, in the middle, Scott Wolchko. So welcome all of you. Thanks for making the time.

Questions & Answers

Yigal Dov Nochomovitz
Citigroup Inc, Research Division - Director

I guess the question I have to start out the session is at a 30,000-foot level, could each of you give your thoughts on what are the ingredients to create a successful cell therapy? What are the things you want to do? And what are the things that you absolutely want to avoid on the path to a product that's a cell-based therapy? So you want to kick it off, Pascal?

Pascal Touchon;Yigal Dov Nochomovitz<
Atara Biotherapeutics, Inc. - President, CEO & Director

Yes, with pleasure. I mean thank you for inviting me, by the way.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot